Teresa Branco
Director of TO BE.
Most women reach menopause without any clear information about what happens to their bodies during this phase. People usually talk about symptoms such as hot flashes, sleep disturbances, or mood swings. However, they rarely discuss what is happening internally, especially in the breast area. When estrogen levels drop abruptly, breast tissue does not simply go into a state of dormancy. On the contrary, it undergoes a transformation.
In addition, it changes its structure, alters its immune environment, and becomes a more favorable environment for the emergence of cancer cells.
In fact, a study published in March 2026 in the journal *Nature Aging* demonstrated exactly this. And it did so with a level of detail and on a scale unprecedented in the scientific literature.
What the study revealed
Researchers from the University of Cambridge and the BC Cancer Agency examined normal breast tissue from 527 women between the ages of 15 and 86. In total, they analyzed more than three million cells—using precision technology that allows them to see what is happening inside each cell. The result? It is the most comprehensive mapping ever conducted of what happens to the breast over the course of a lifetime.
In summary, breast tissue undergoes a profound and widespread transformation with age. This transformation accelerates around age 50—precisely the average age of menopause.
What Changes in Breast Tissue After Menopause
First, breast tissue is composed of three types of cells: those that line the ducts and lobules (epithelial cells), those that form the supporting structure (stroma), and those responsible for local immune surveillance.
However, with menopause, the number of cells of each type decreases dramatically. All of them decrease. As a result, the tissue loses its organization. The lobules—the functional units where most tumors originate—shrink significantly. Fat takes their place. However, it is what happens to the local defense system that most concerns researchers.
The local immune defense weakens
In young tissue, there is an active population of immune cells—B lymphocytes—that detect and eliminate abnormal cells before they cause problems. As we age, these B lymphocytes decrease significantly. In their place, other types of immune cells emerge, whose profile is associated with low-grade chronic inflammation. Paradoxically, this state does not combat dangerous cells—it merely tends to “accommodate” them.
Furthermore, the local immune system generally ceases to function as a barrier. And that’s not all: the study also shows that the cells lose their ability to communicate with one another. In young tissue, there is a dense network of signals between cells that limits abnormal growth. However, with age, this network gradually disappears; the cells drift apart, and the space—which was previously controlled—becomes more permissive—and it is in this context that tumors can arise and grow with less resistance.
In summary, the study confirms:
- Breast tissue loses its structure and cellular density as we age;
- The lobules, the primary site of tumor origin, shrink dramatically after menopause;
- The immune microenvironment becomes pro-inflammatory and less vigilant;
- The cellular interactions that protect against cancer weaken with age.
Why is breast cancer more common after menopause?
In Portugal, breast cancer is the most commonly diagnosed cancer in women, and its incidence increases progressively starting at age 50. For decades, this relationship was attributed primarily to cumulative exposure to estrogens throughout a woman’s reproductive life.
However, this study adds a dimension that goes beyond hormones: the tissue itself ages and becomes more vulnerable to tumor development— regardless of other risk factors.
Thus, menopause marks the point at which the abrupt drop in estrogen coincides with this structural transformation. As a result, the body is simultaneously more vulnerable and less able to defend itself.
What does this mean for clinical practice?
Of course, this study does not raise any new concerns. It simply provides solid scientific evidence for something that clinicians with experience in this area had already observed. In fact, menopause is not just a hormonal transition. It is a profound change in breast tissue, with direct implications for cancer risk.
Breast screening should not be sporadic
Regular screening—mammograms and ultrasounds—remains essential for postmenopausal women. And not just because tumors become more common. It is also because the tissue in which they develop has distinct characteristics. For this reason, early diagnosis continues to have the greatest impact.
The decision regarding hormone replacement therapy requires an individualized assessment
Since breast tissue becomes more vulnerable after menopause, the decision to start, continue, or adjust hormone replacement therapy requires discussion with your doctor.
Recently, the FDA decided to remove the warning associated with estrogen alone. This decision has clarified the situation. As a result, it allows for a more balanced approach grounded in scientific evidence.
Controlling inflammation has real clinical implications
The inflammatory profile observed in aging breast tissue is not an isolated phenomenon. On the contrary, it reflects a systemic inflammatory state that menopause tends to amplify.
Therefore, combating low-grade chronic inflammation is essential. Thus, through diet, body composition management, and structured clinical monitoring, we establish a fundamental pillar in promoting women’s health during this stage of life.
When to Seek Specialized Care
Menopause is a time that requires more than just managing hot flashes and sleep disturbances. Above all, it requires understanding what is happening in your body. Then, it is essential to take action based on that knowledge.
A specialized clinical evaluation is recommended when:
- The woman is going through perimenopause or menopause without structured medical care;
- There is a personal or family history of breast cancer, and the issue of screening has never been discussed in depth;
- Hormone replacement therapy was prescribed without an individualized risk-benefit assessment;
- There are symptoms associated with menopause—such as weight changes, fatigue, sleep disturbances, and vaginal dryness—that are not being addressed clinically;
- Chronic inflammation or body composition have never been assessed in this context.
First of all, most of these situations have a clear clinical solution. The first step is to consult with someone who is familiar with the evidence and knows how to apply it to each individual case.
At TO BE., we treat every woman as a whole person
TO BE. is a medical clinic where scientific rigor is combined with an integrated care model. Through a multidisciplinary team that brings together Endocrinology, Internal Medicine, Clinical Nutrition, Exercise Physiology, and Healthy Longevity Medicine, we provide personalized care to address the needs that most impact women’s health and longevity. Our commitment is to transform science into quality of life.
Focusing on menopause and cancer risk, the clinic works to ensure that every woman understands what is happening in her body, is aware of the available options, and makes informed decisions—without fear, without pressure, and with close, ongoing support.
Because menopause isn't the end of anything. It's a time that, with the right support, can be experienced with better health, greater knowledge, and a higher quality of life.
